28230-35-5

Basic information

• Product Name: 2-amino-5-bromo-N-hydroxybenzamide
• Synonyms: 2-Amino-5-bromo-N-hydroxybenzamide; benzamide, 2-amino-5-bromo-N-hydroxy-
• CAS NO: 28230-35-5
• Molecular Formula: C₇H₇BrN₂O₂
• Molecular Weight: 231.0467
• Mol File: 28230-35-5.mol
• Article Data: 2

Chemical Properties

• Density: 1.787g/cm³
• Refractive Index: 1.677
• CAS DataBase Reference: 2-amino-5-bromo-N-hydroxybenzamide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-amino-5-bromo-N-hydroxybenzamide(28230-35-5)
• EPA Substance Registry System: 2-amino-5-bromo-N-hydroxybenzamide(28230-35-5)

Safety Data

• Hazardous Substances Data: 28230-35-5(Hazardous Substances Data)

Upstream product

• 5794-88-7 5-Bromo-2-aminobenzoic acid 

Downstream Products

• 39513-26-3 5-bromo-1,3-dihydro-benzoimidazol-2-one 

Relevant articles and documents

Parallel synthesis and in vitro activity of novel anthranilic hydroxamate-based inhibitors of the prostaglandin H2 synthase peroxidase activity

Currently available non-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin are directed at the cyclooxygenase (COX) site, but not the peroxidase (POX) activity of prostaglandin H2 synthase (PGHS). They are thus unable to inhibit the free-radical induced tissue injury associated with PGHS peroxidase activity, which can occur independently of the COX site. A lead compound, anthranilic hydroxamic acid (AHA) was found to have significant PGHS-POX inhibitory activity (IC50 = 72 μM). To define the critical parameters for PGHS-POX inhibition, we investigated 29 AHA derivatives, synthesised from their acid precursors, using solid phase synthesis. In vitro analysis demonstrated a ten-fold improvement in inhibition with 3,5-diiodoanthranilic hydroxamic acid (IC50 = 7 μM). The Royal Society of Chemistry 2005.